Abstract 13518: Low Skeletal Muscle Mass Index is Associated With Cardiovascular Events in Patients After ST-segment Elevation Myocardial Infarction
Introduction: Although it has been implicated the association between low skeletal muscle mass and cardiovascular diseases, the prognostic value of skeletal muscle mass in patients with ST-segment elevation myocardial infarction (STEMI) is unclear.
Hypothesis: We assessed the hypothesis that low skeletal muscle mass index (SMMI) is associated with an increased risk of secondary cardiovascular events in patients with STEMI.
Methods: A total of 200 patients with STEMI were enrolled. SMMI was estimated from dual-energy X-ray absorptiometry scan before discharge, and calculated by dividing appendicular skeletal muscle mass (kg) by height squared (m2). The patients were divided into low and high SMMI groups using the first tertile of SMMI. Low SMMI was defined as ≤6.843 kg/m2 for men and ≤5.321 kg/m2 for women. All patients were followed for cardiovascular events, which consist of cardiovascular deaths, nonfatal myocardial infarctions, nonfatal ischemic strokes, and congestive heart failure.
Results: During follow-up (median 340 days [interquartile ranges 298 and 389]), 15 patients experienced cardiovascular events (1 cardiovascular death, 6 myocardial infarction, 6 stroke, and 3 congestive heart failure). The event rate at 1 year after STEMI was significantly higher in patients with low SMMI (15.5%) than with high SMMI (2.5%) (log-rank p<0.001) (Figure). Even after adjustment for the propensity score which was calculated with age, gender, height, weight, risk factors and medications, patients with low SMMI had 5.8-fold higher risk of subsequent cardiovascular events compared to those without (Adjusted hazard ratio 5.86, 95% confidence interval 1.18 to 35.28, p=0.03).
Conclusion: Among patients with STEMI, low SMMI was significantly and independently associated with an increased risk of future cardiovascular events.
Author Disclosures: R. Satou: None. Y. Matsuzawa: None. E. Akiyama: None. H. Suzuki: None. C. Kawashima: None. M. Konishi: None. Y. Kimura: None. K. Hashiba: None. N. Maejima: None. N. Iwahashi: None. K. Hibi: Research Grant; Modest; AstraZeneca Co., Ltd, MSD Co., Ltd, Solve Co., Ltd, Biosensors Japan Co., Ltd, Teijin Pharma Co., Ltd, Terumo Co., Ltd, Mochida Pharmaceutical Co., Ltd. Research Grant; Significant; Goodman Co., Ltd, Medtronic Japan Co., Ltd, St. Jude Medical Japan Co., Ltd. Honoraria; Modest; Daiichi-Sankyo Co., Ltd, Boston Scientific Japan Co., Ltd. Consultant/Advisory Board; Modest; Terumo Co., Ltd, St. Jude Medical Japan Co., Ltd. M. Kosuge: None. T. Ebina: None. S. Sumita: None. K. Kimura: Research Grant; Significant; Toa Eiyo Ltd, Bayer, MSD, Astellas, Astrazeneca, Sanofi, Eli Lilly Japan, Research Institute for Production Development, Pfizer, Shionogi, Kowa-souyaku, Daiichi-Sankyo, Mitsubishi Tanabe, Nihon-Boehringer-Ingelheim, Takeda, Otsuka, Ono. Honoraria; Modest; Astrazeneca, Toa Eiyo Ltd. Honoraria; Significant; MSD, Bayer, Daiichi-Sankyo.
- © 2016 by American Heart Association, Inc.